Quantcast

Latest Bioethics Stories

2014-04-01 20:21:49

DUBLIN, April 2, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/pttfr4/cancer_gene) has announced the addition of the "Cancer Gene Therapy Market Analysis" [http://www.researchandmarkets.com/research/pttfr4/cancer_gene ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The gene therapy market has undergone series of transformation from the initial days of research to current clinical...

2014-03-31 08:29:05

MELBOURNE, Australia, March 31, 2014 /PRNewswire/ -- Prana Biotechnology (ASX:PBT/NASDAQ:PRAN) has today released the top line results of the 12-month Phase II Imaging trial in Alzheimer's Disease ("IMAGINE" Trial), based on draft results. Prana's PBT2 did not meet its primary endpoint of a statistically significant reduction in the levels of beta-amyloid plaques in the brains of prodromal/mild Alzheimer's disease patients, as measured using PiB-PET Standardized Uptake Value...

2014-03-22 08:21:21

- FEATURE and JUNCTURE data show secukinumab delivered significant skin clearance at week 12(1,2) EAST HANOVER, N.J., March 22, 2014 /PRNewswire/ -- Novartis today announced results from the Phase III FEATURE and JUNCTURE studies showing secukinumab (AIN457), a selective interleukin-17A (IL-17A) inhibitor, met both co-primary endpoints at Week 12 based on Psoriasis Area and Severity Index (PASI) 75 and Investigator's Global Assessment modified 2011 (IGA mod 2011) 0/1 response...

2014-03-20 23:03:41

BioFire Defense of Salt Lake City, Utah announced today that it was awarded the Next Generation Diagnostic System (NGDS) Technology Development contract by the US Department of Defense. Salt Lake City, UT (PRWEB) March 20, 2014 BioFire Defense, LLC of Salt Lake City, UT announced today that it was awarded the Next Generation Diagnostic System (NGDS) Technology Development contract by the US Department of Defense (DoD) after 12 months of competitive prototyping. The 8 year $240M biodefense...

Multiple Sclerosis May Benefit From Statins
2014-03-19 10:09:06

Brett Smith for redOrbit.com - Your Universe Online At first, multiple sclerosis is recognized by sporadic neurological symptoms – a condition called relapsing-remitting MS. Within a decade or so, greater than 50 percent of patients acquire secondary progressive MS, a continuous deterioration of symptoms and boost in disability. Currently, there are no approved drugs for treating this later stage of the disease. However, a newly published study in the UK medical journal The Lancet has...

Are Your Pets Benefiting From Their Pain Medication?
2014-03-13 15:17:15

Tracey Peake, North Carolina State University How do you know that your pet is benefiting from its pain medication? A new clinical trial design could help overcome pet owners’ unconscious observation bias and determine whether the drugs they test are effective. When animals are recruited for clinical trials, particularly for pain medications, researchers must rely on owner observation to determine whether the medication is working. Sounds simple enough, but as it turns out, human and...

2014-03-11 23:33:04

Achieve is conducting a phase II, placebo-controlled, multi dose, 24-week clinical study to evaluate the efficacy and safety of a new autoimmune medication in participants living with systemic lupus erythematosus (SLE). Birmingham, Alabama (PRWEB) March 11, 2014 *To see if you qualify for this Lupus Clinical Trial in Birmingham, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/) or contact us directly at (205) 380-6434. There is no cost to participate, no...

2014-03-09 23:02:12

Panel of experts seeks to answer the complex legal, bioethical and medical issues raised by costly advances in drug development and research. New York, NY (PRWEB) March 09, 2014 Linda A. Malek, Chair of the Healthcare Practice at Moses & Singer LLP participated in a panel on “The Rising Cost of Cancer Drugs and Cancer Research” at the New York City Bar Association on March 6, 2014. The program was sponsored by the Bioethical Issues Committee and moderated by renowned bioethicist...

2014-03-07 23:22:43

Art Caplan will discuss "End of Life: Legal, Medical and Ethical Issues" for the annual Batdorf Lecture at Alvernia University, March 18, 2014. Reading, PA (PRWEB) March 07, 2014 Art Caplan, considered one of the foremost experts on Bioethics and the ethics of healthcare reform, will discuss the legal, medical and ethical issues surrounding end of life for Alvernia University’s annual Batdorf Lecture, March 18, 5 p.m., in the McGlinn Conference Center. The lecture will be...

2014-03-05 08:20:33

Hawaii Biotech Receives DoD Contract to Develop Anti-Botulism Drug HONOLULU, March 5, 2014 /PRNewswire/ -- The Department of Defense, Defense Threat Reduction Agency, has awarded Hawaii Biotech, Inc., a contract to continue developing drugs to block botulinum toxin, the toxin that causes the life-threatening disease, botulism. There is no therapeutic drug currently available for the treatment of botulism. The award has a first-year period of performance through early 2014, followed...


Latest Bioethics Reference Libraries

OncoMouse
2013-10-02 09:29:43

The OncoMouse or Harvard Mouse is a type of laboratory mouse that has been genetically modified utilizing modification designed by Philip Leder and Timothy A. Stewart, of Harvard University, to carry a certain gene called an activated oncogene. The activated oncogene considerably increases the mouse’s vulnerability to cancer, therefore making the mouse suitable for cancer research. The rights to the invention were owned by DuPont until recently. The USPTO found that the patent expired in...

More Articles (1 articles) »
Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related